Investors / United States / Myeloma Investment Fund
Myeloma Investment Fund
Investor · Norwalk, CT, United States · North America
The Myeloma Investment Fund is a venture philanthropy fund and wholly owned subsidiary of the Multiple Myeloma Research Foundation. It invests in companies, clinical assets and technologies in oncology to advance new therapies for multiple myeloma, reinvesting all returns into the fund.
Invests inHealthcare & Biotech
In its own wordsoncologymultiple myelomabiotechventure philanthropytherapeuticsdrug development
Your fit with Myeloma Investment Fund
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsMyeloma Investment Fund lists 15 checked portfolio companies on its own site and is named in 1 funding round. Its most frequent entry is Series A, 100% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 86% of its companies are based in United States. It invests most often alongside RA Capital, Viva BioInnovator and 2048 Ventures.
Counts come from funding rounds that name Myeloma Investment Fund, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Myeloma Investment Fund's whole history. Rounds on record name 1 company; its own site lists 15. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundMyeloma Investment Fund does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 100% |
| Series B | 0% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 0 |
| '26 | 0 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 39th | 15 companies |
| Recent activity | 46th | 0 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 69th | 7% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 42th | 2 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| RA Capital | 2 |
| Viva BioInnovator | 2 |
| 2048 Ventures | 1 |
| ARK Venture Fund | 1 |
| Avalon BioVentures | 1 |
| Bija Ventures | 1 |
| Brainstorm Ventures | 1 |
| California Innovation Fund | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers15100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Myeloma Investment Fund head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Myeloma Investment Fund| Date | Company | Stage |
|---|---|---|
| 13 May 2025 | Series A |
Round details for Myeloma Investment Fund
Amounts, full round histories and every co-investor in Myeloma Investment Fund's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
15 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Abcuro develops therapies for autoimmune diseases and cancer. | Healthcare & Biotech | Portfolio page | ||
| The company builds immunotherapies for cancer patients by testing millions of candidates to find the best therapies. | Healthcare & Biotech | Portfolio page | ||
| CytoImmune Biologics manufactures autologous cell therapies in an ISO 7 cleanroom suite at the University of Puerto Rico's Molecular Sciences Research Center in San Juan. | Healthcare & Biotech | Portfolio page | ||
| Envisagenics discovers therapeutic targets in oncology and neurodegeneration using an AI platform that targets RNA splicing | Healthcare & Biotech | Portfolio page | ||
| Fortis Therapeutics is transforming outcomes for patients with cancer by developing novel therapeutics focused on CD46 | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Luminary Therapeutics is a clinical-stage company developing innovative allogeneic cell therapies to target solid tumors and autoimmune disorders | Healthcare & Biotech | Portfolio page | ||
| Nammi Therapeutics develops products that focus immune activation at the site of tumors, sparing the life-changing side effects of systemic immune activation. | Healthcare & Biotech | Portfolio page | ||
| Nectin Therapeutics is developing immuno-oncology and ADC breakthrough therapies | Healthcare & Biotech | Portfolio page | ||
| Reverb Therapeutics creates medicines that intelligently reshape the body’s immune system to fight cancer and other life-threatening conditions more effectively. | Healthcare & Biotech | Portfolio page | ||
| Stylus Medicine is developing in vivo genetic medicines to unlock cures. | Healthcare & Biotech | May 2025Series A | Page + round | |
| Telo Therapeutics is an oncology therapeutics company developing innovative targeted therapies to treat patients with cancers refractory to existing medicines. | Healthcare & Biotech | Portfolio page | ||
| The company is developing novel dual targeting antibody drugs to treat cancer | Healthcare & Biotech | Portfolio page | ||
| Triumvira Immunologics develops T cell therapies for the treatment of cancers. | Healthcare & Biotech | Portfolio page | ||
| Umoja Biopharma develops in vivo CAR T cell therapies for the treatment of cancers and other conditions. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- myelomainvestmentfund.org
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 13 May 2025
- Companies checked
- 15
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Myeloma Investment Fund's profile as data
Pull Myeloma Investment Fund's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/myelomainvestmentfund.org
# also
GET /v1/firms/myelomainvestmentfund.org/portfolio
GET /v1/firms/myelomainvestmentfund.org/coinvestors
GET /v1/firms/myelomainvestmentfund.org/news